Parameters | Distribution | Mean | SE | References |
---|---|---|---|---|
Costs of prevention program | Â | Â | Â | Â |
Annual costs of existing prevention programs | Gamma | 24 | Â | |
Cost of HIV vaccine per course | Gamma | 3,500 | Â | [12] |
Individual cost of community engagement | Gamma | 937* | Â | Â |
Cost of HIV screening (ELISA) for vaccine acceptance | Gamma | 125 | Â | [47] |
Cost of pre-counselling for all vaccinations | Gamma | 141 | Â | [47] |
Cost of post-counselling for vaccine acceptance | Gamma | 58 | Â | [47] |
Costs of treatment program | Â | Â | Â | Â |
Costs of asymptomatic treatment | Â | Â | Â | Â |
Laboratory cost for asymptomatic patient | Gamma | 8,155 | Â | [29] |
Hospital service cost of asymptomatic patient | Gamma | 2,502 | Â | [29] |
OPD cost of asymptomatic patient | Gamma | 2,502 | Â | [29] |
Costs of symptomatic treatment | Â | Â | Â | Â |
Lab test cost for symptomatic patient | Gamma | 8,931 | Â | [29] |
Opportunity infection treatment cost of symptomatic patient | Gamma | 4,739 | Â | [29] |
Hospital service cost of symptomatic patient | Gamma | 9,104 | Â | [29] |
OPD cost of symptomatic patient | Gamma | 2,502 | Â | [29] |
IPD cost of symptomatic patient | Gamma | 6,227 | Â | [29] |
Costs of AIDS treatment | Â | Â | Â | Â |
Opportunity infection treatment cost of AIDS patient | Gamma | 4,739 | Â | [29] |
Hospital service cost of AIDS patient | Gamma | 9,104 | Â | [29] |
OPD cost of AIDS patient | Gamma | 2,502 | Â | [29] |
IPD cost of AIDS patient | Gamma | 6,227 | Â | [29] |
Annual drug costs of the first-line ART regimens (mg): | Gamma | 8,184†| 1,858†|  |
1. d4T(30)+3TC(150)+NVP(200) or | Â | Â | Â | Â |
2. d4T(30) + 3TC(150) + EFV (600) or | Â | Â | Â | Â |
3. AZT(100/200/250/300)+3TC(150)+NVP(200) or | Â | Â | Â | Â |
4. AZT(100/200/300)+3TC(150)+EFV(600) | Â | Â | Â | Â |
Annual drug costs of the second-line ART regimens (mg): | Gamma | 32,478†| 5,772†|  |
1. ddI(250)+3TC(150)+NVP(200) or | Â | Â | Â | Â |
2. ddI(250)+3TC(150)+EFV(600) or | Â | Â | Â | Â |
3. TDF(300)+3TC(150)+NVP(200) or | Â | Â | Â | Â |
4. TDF(300)+3TC(150/300)+EFV(600) | Â | Â | Â | Â |
Annual drug costs of the third-line ART regimens (mg): | Gamma | 15,682†| 2,080†|  |
1. AZT(100/200/300)+3TC(150)+Boosted PIs‡ or |  |  |  |  |
2. d4T(30)+3TC(150)+Boosted PIs‡ or |  |  |  |  |
3. TDF(300)+3TC(150)+Boosted PIs‡ or |  |  |  |  |
4. ddI(250)+3TC(150)+Boosted PIs‡ or |  |  |  |  |
5. AZT(100/200/300)+ddI(250)+Boosted PIs‡ or |  |  |  |  |
6. AZT(100/200/300)+TDF(300)+Boosted PIs‡ or |  |  |  |  |
7. AZT(100/200/300)+3TC(150)+TDF(300)+Boosted PIs‡ |  |  |  |  |
Annual costs of lab test of first-line ART regimen in the first year | Gamma | 7,671 | Â | [48] |
Annual costs of lab test of first-line ART regimen in subsequence years | Gamma | 4,210 | Â | [48] |
Annual costs of lab test of the second-line ART regimen | Gamma | 4,140 | Â | [48] |
Annual costs of lab test of the third-line ART regimen | Gamma | 4,163 | Â | [48] |